Effect of video conferencing between primary and secondary care specialists on type 2 diabetes medication

Thim Prætorius; Anne Sofie Baymler Lundberg; Eskild Klausen Fredslund; Niklas Blach Rossen; Søren Gregersen; Anders Prior; Esben Søndergaard; Søren Tang Knudsen; Annelli Sandbæk

doi:10.1038/s41746-025-01570-w

Effect of video conferencing between primary and secondary care specialists on type 2 diabetes medication

Thim Prætorius, Anne Sofie Baymler Lundberg, Eskild Klausen Fredslund, Niklas Blach Rossen, Søren Gregersen, Anders Prior, Esben Søndergaard, Søren Tang Knudsen, Annelli Sandbæk

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Journal article › Research › peer-review

Abstract

Although promising, the clinical impact of video conferencing between primary and secondary care specialists lacks trial evidence. We conducted a two-arm RCT (clinicaltrials.gov: NCT05268081) to evaluate whether four video conferences over 12 months between endocrinologists and general practitioners improved medication for people with type 2 diabetes (T2D). Twenty-seven of 100 general practices in Aarhus, Denmark were matched and randomized. Primary outcomes: the proportion of people with T2D and 1) ischemic heart disease treated with glucagon-like peptide 1 receptor agonist (GLP1-RA) and/or sodium glucose cotransporter 2 inhibitor (SGLT2I), 2) micro/macro-albuminuria treated with angiotensin-converting-enzyme-inhibitor (ACE) or angiotensin-2-receptorantagonist (AT2), 3) low-density lipoprotein >2.5 mmol/L treated with statins. Results showed a 17.6% difference [95% CI 4.6%; 30.7%] in GLP1-RA/SGLT2I prescriptions and minimal differences for ACE/AT2 (−1.1% [95% CI −2.8%; 0.6%]) and statins (0.0% [95% CI −3.5%; 3.6%]), attributed to a ceiling effect. Video conferencing can help bridge treatment gaps, particularly for recently updated guidelines.

Original language	English
Article number	179
Journal	npj Digital Medicine
Volume	8
Issue	1
ISSN	2398-6352
DOIs	https://doi.org/10.1038/s41746-025-01570-w
Publication status	Published - Dec 2025

Access to Document

10.1038/s41746-025-01570-wLicence: Unspecified

Library access?

Check availability with the Royal Danish Library

Cite this

@article{c74300954b5d4bac853acdafc2e715f9,

title = "Effect of video conferencing between primary and secondary care specialists on type 2 diabetes medication",

abstract = "Although promising, the clinical impact of video conferencing between primary and secondary care specialists lacks trial evidence. We conducted a two-arm RCT (clinicaltrials.gov: NCT05268081) to evaluate whether four video conferences over 12 months between endocrinologists and general practitioners improved medication for people with type 2 diabetes (T2D). Twenty-seven of 100 general practices in Aarhus, Denmark were matched and randomized. Primary outcomes: the proportion of people with T2D and 1) ischemic heart disease treated with glucagon-like peptide 1 receptor agonist (GLP1-RA) and/or sodium glucose cotransporter 2 inhibitor (SGLT2I), 2) micro/macro-albuminuria treated with angiotensin-converting-enzyme-inhibitor (ACE) or angiotensin-2-receptorantagonist (AT2), 3) low-density lipoprotein >2.5 mmol/L treated with statins. Results showed a 17.6% difference [95% CI 4.6%; 30.7%] in GLP1-RA/SGLT2I prescriptions and minimal differences for ACE/AT2 (−1.1% [95% CI −2.8%; 0.6%]) and statins (0.0% [95% CI −3.5%; 3.6%]), attributed to a ceiling effect. Video conferencing can help bridge treatment gaps, particularly for recently updated guidelines.",

author = "Thim Pr{\ae}torius and Lundberg, {Anne Sofie Baymler} and Fredslund, {Eskild Klausen} and Rossen, {Niklas Blach} and S{\o}ren Gregersen and Anders Prior and Esben S{\o}ndergaard and Knudsen, {S{\o}ren Tang} and Annelli Sandb{\ae}k",

year = "2025",

month = dec,

doi = "10.1038/s41746-025-01570-w",

language = "English",

volume = "8",

journal = "npj Digital Medicine",

issn = "2398-6352",

publisher = "Nature Publishing Group",

number = "1",

}

Effect of video conferencing between primary and secondary care specialists on type 2 diabetes medication. / Prætorius, Thim ; Lundberg, Anne Sofie Baymler; Fredslund, Eskild Klausen et al.
In: npj Digital Medicine, Vol. 8, No. 1, 179, 12.2025.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Journal article › Research › peer-review

TY - JOUR

T1 - Effect of video conferencing between primary and secondary care specialists on type 2 diabetes medication

AU - Prætorius, Thim

AU - Lundberg, Anne Sofie Baymler

AU - Fredslund, Eskild Klausen

AU - Rossen, Niklas Blach

AU - Gregersen, Søren

AU - Prior, Anders

AU - Søndergaard, Esben

AU - Knudsen, Søren Tang

AU - Sandbæk, Annelli

PY - 2025/12

Y1 - 2025/12

N2 - Although promising, the clinical impact of video conferencing between primary and secondary care specialists lacks trial evidence. We conducted a two-arm RCT (clinicaltrials.gov: NCT05268081) to evaluate whether four video conferences over 12 months between endocrinologists and general practitioners improved medication for people with type 2 diabetes (T2D). Twenty-seven of 100 general practices in Aarhus, Denmark were matched and randomized. Primary outcomes: the proportion of people with T2D and 1) ischemic heart disease treated with glucagon-like peptide 1 receptor agonist (GLP1-RA) and/or sodium glucose cotransporter 2 inhibitor (SGLT2I), 2) micro/macro-albuminuria treated with angiotensin-converting-enzyme-inhibitor (ACE) or angiotensin-2-receptorantagonist (AT2), 3) low-density lipoprotein >2.5 mmol/L treated with statins. Results showed a 17.6% difference [95% CI 4.6%; 30.7%] in GLP1-RA/SGLT2I prescriptions and minimal differences for ACE/AT2 (−1.1% [95% CI −2.8%; 0.6%]) and statins (0.0% [95% CI −3.5%; 3.6%]), attributed to a ceiling effect. Video conferencing can help bridge treatment gaps, particularly for recently updated guidelines.

AB - Although promising, the clinical impact of video conferencing between primary and secondary care specialists lacks trial evidence. We conducted a two-arm RCT (clinicaltrials.gov: NCT05268081) to evaluate whether four video conferences over 12 months between endocrinologists and general practitioners improved medication for people with type 2 diabetes (T2D). Twenty-seven of 100 general practices in Aarhus, Denmark were matched and randomized. Primary outcomes: the proportion of people with T2D and 1) ischemic heart disease treated with glucagon-like peptide 1 receptor agonist (GLP1-RA) and/or sodium glucose cotransporter 2 inhibitor (SGLT2I), 2) micro/macro-albuminuria treated with angiotensin-converting-enzyme-inhibitor (ACE) or angiotensin-2-receptorantagonist (AT2), 3) low-density lipoprotein >2.5 mmol/L treated with statins. Results showed a 17.6% difference [95% CI 4.6%; 30.7%] in GLP1-RA/SGLT2I prescriptions and minimal differences for ACE/AT2 (−1.1% [95% CI −2.8%; 0.6%]) and statins (0.0% [95% CI −3.5%; 3.6%]), attributed to a ceiling effect. Video conferencing can help bridge treatment gaps, particularly for recently updated guidelines.

UR - http://www.scopus.com/inward/record.url?scp=105001163533&partnerID=8YFLogxK

U2 - 10.1038/s41746-025-01570-w

DO - 10.1038/s41746-025-01570-w

M3 - Journal article

C2 - 40148532

SN - 2398-6352

VL - 8

JO - npj Digital Medicine

JF - npj Digital Medicine

IS - 1

M1 - 179

ER -

Effect of video conferencing between primary and secondary care specialists on type 2 diabetes medication

Abstract

Access to Document

Library access?

Other files and links

Fingerprint

Cite this